Education
About Us
Working with TipRanks
Follow Us
CytomX Therapeutics Inc (CTMX)
NASDAQ:CTMX
CTMX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.56 - $5.85
Previous CloseN/A
Volume1.08M
Average Volume (3M)2.65M
Market Cap
$49.27M
Enterprise Value-$8.74M
Total Cash (Recent Filing)$38.05M
Total Debt (Recent Filing)$9.38M
Price to Earnings (P/E)1.6
Beta1.52
Next Earnings
May 07, 2025EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.39
Shares Outstanding80,099,890
10 Day Avg. Volume1,351,369
30 Day Avg. Volume2,648,596
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.39
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.06
Enterprise Value/Ebitda-0.33
Forecast
1Y Price Target
$4.69Price Target Upside694.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
CytomX Therapeutics News
PremiumCompany Announcements
CytomX Therapeutics’ Earnings Call Highlights Progress and Challenges
PremiumCompany Announcements
CytomX Therapeutics Reports Strong 2024 Financial Results
PremiumCompany Announcements
CytomX Therapeutics Announces Executive Departure and Severance
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCytomX reported a net profit of $0.38 per share, surpassing the prior estimate of $0.14 per share, indicating strong financial performance.
Pipeline PrioritizationCytomX announced a corporate restructuring with a focus on pipeline priorities, leading with CX-2051 development in colorectal cancer.
Revenue GrowthCytomX recorded $33.4M in revenue for 3Q24, exceeding the most recent estimate of $25.0M, showcasing robust revenue growth.
Bears Say
Clinical RisksRisks include the emergence of unexpected side effects with CX-904, CX-2051, CX-801, or probody T-cell bispecifics in future clinical data.
Pancreatic Cancer DevelopmentDevelopment in pancreatic cancer has historically faced numerous clinical challenges, posing potential obstacles for CytomX.
Pipeline SetbacksThe discontinuation of CX-904 adds to a history of pipeline setbacks for CytomX, creating challenges in advancing its programs.
---
Ownership Overview
2.50% Insiders
7.67% Mutual Funds
28.88% Other Institutional Investors
55.98% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CTMX FAQ
What was CytomX Therapeutics Inc’s price range in the past 12 months?
CytomX Therapeutics Inc lowest stock price was $0.56 and its highest was $5.85 in the past 12 months.
What is CytomX Therapeutics Inc’s market cap?
CytomX Therapeutics Inc’s market cap is $49.27M.
When is CytomX Therapeutics Inc’s upcoming earnings report date?
CytomX Therapeutics Inc’s upcoming earnings report date is May 07, 2025 which is in 41 days.
How were CytomX Therapeutics Inc’s earnings last quarter?
CytomX Therapeutics Inc released its earnings results on Mar 06, 2025. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of -$0.195 by $0.415.
Is CytomX Therapeutics Inc overvalued?
According to Wall Street analysts CytomX Therapeutics Inc’s price is currently Undervalued.
Does CytomX Therapeutics Inc pay dividends?
CytomX Therapeutics Inc does not currently pay dividends.
What is CytomX Therapeutics Inc’s EPS estimate?
CytomX Therapeutics Inc’s EPS estimate is 0.06.
How many shares outstanding does CytomX Therapeutics Inc have?
CytomX Therapeutics Inc has 80,099,890 shares outstanding.
What happened to CytomX Therapeutics Inc’s price movement after its last earnings report?
CytomX Therapeutics Inc reported an EPS of $0.22 in its last earnings report, beating expectations of -$0.195. Following the earnings report the stock price went up 6.452%.
Which hedge fund is a major shareholder of CytomX Therapeutics Inc?
Currently, no hedge funds are holding shares in CTMX
---
CytomX Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.69 (694.92% Upside)
$4.69 (694.92% Upside)
Blogger Sentiment
Bullish
CTMX Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 393.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $47.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 17.8%
Last 30 Days ▲ 17.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.26%
12-Months-Change
Fundamentals
Return on Equity
-58.97%
Trailing 12-Months
Asset Growth
-40.22%
Trailing 12-Months
Company Description
CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
---
CTMX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in advancing clinical programs and strong financial performance, especially through strategic partnerships and increased revenue. However, challenges include the discontinuation of CX-904 and a decrease in cash reserves. Overall, the positive aspects slightly outweigh the negatives.Read More>---
CTMX Stock 12 Month Forecast
Average Price Target
$4.69
▲(694.92% Upside)
Technical Analysis
Xoma
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Blueprint Medicines
―
Adaptimmune Therapeutics
―
Best Analysts Covering CTMX
1 Year
1 Year Success Rate
4/11 ratings generated profit
1 Year Average Return
-21.69%
reiterated a buy rating 3 months ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -21.69% per trade.
---